Boryung challenged Eisai's patent for Lenvima, a liver cancer treatment. It is interpreted as a strategy to spur the anti-cancer drug business, which has been strongly driving since 2020. According to the pharmaceutical industry on the 29th, Boryung recently filed a passive judgment on the scope of rights and a judgment on invalidity in three Lenvima patents at the same time.

Lenvima is a treatment for liver cancer in Eisai. It is used in the primary treatment of liver cancer along with Nexavar and Tecentriq+Avastin. According to IQVIA, a pharmaceutical market research firm, Lenvima's sales last year were 15.8 billion won. It has increased by 30% compared to 12.2 billion won in 2020. This year, it poste